Literature DB >> 11902564

Mantle-cell lymphoma.

I Barista1, J E Romaguera, F Cabanillas.   

Abstract

During the past decade, mantle-cell lymphoma has been established as a new disease entity. The normal counterparts of the cells forming this malignant lymphoma are found in the mantle zone of the lymph node, a thin layer surrounding the germinal follicles. These cells have small to medium-sized nuclei, are commonly indented or cleaved, and stain positively with CD5, CD20, cyclin D1, and FMC7 antibodies. Because of its morphological appearance and a resemblance to other low-grade lymphomas, many of which grow slowly, this lymphoma was initially thought to be an indolent tumour, but its natural course was not thoroughly investigated until the 1990s, when the BCL1 oncogene was identified as a marker for this disease. Mantle-cell lymphoma is a discrete entity, unrelated to small lymphocytic or small-cleaved-cell lymphomas.

Entities:  

Mesh:

Year:  2001        PMID: 11902564     DOI: 10.1016/S1470-2045(00)00255-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  18 in total

1.  Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? For.

Authors:  Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-09       Impact factor: 9.236

2.  Detection of cyclin D1 in B cell lymphoproliferative disorders by flow cytometry.

Authors:  P Jain; G M Giustolisi; S Atkinson; M O Elnenaei; R Morilla; K Owusu-Ankomah; F Rafiq-Mohammed; E Matutes; A Wotherspoon; D Catovsky
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

3.  Blastic Transformation of a Mantle Cell Lymphoma Presenting as an Enlarging Unilateral Orbital Mass.

Authors:  Matthew A De Niear; John P Greer; Adam Seegmiller; Louise A Mawn
Journal:  Ocul Oncol Pathol       Date:  2018-11-16

4.  A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.

Authors:  Tiziana D'Agaro; Antonella Zucchetto; Filippo Vit; Tamara Bittolo; Erika Tissino; Francesca Maria Rossi; Massimo Degan; Francesco Zaja; Pietro Bulian; Michele Dal Bo; Simone Ferrero; Marco Ladetto; Alberto Zamò; Valter Gattei; Riccardo Bomben
Journal:  Haematologica       Date:  2019-02-28       Impact factor: 9.941

5.  SOX11 regulates the pro-apoptosis signal pathway and predicts a favorable prognosis of mantle cell lymphoma.

Authors:  Wenjuan Yang; Yanying Wang; Zhen Yu; Zengjun Li; Gang An; Wei Liu; Rui Lv; Liping Ma; Shuhua Yi; Lugui Qiu
Journal:  Int J Hematol       Date:  2017-04-20       Impact factor: 2.490

6.  Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.

Authors:  Wolfgang Lamm; Hannes Kaufmann; Markus Raderer; Martha Hoffmann; Andreas Chott; Christoph Zielinski; Johannes Drach
Journal:  Haematologica       Date:  2011-04-12       Impact factor: 9.941

7.  Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma.

Authors:  Kai Song; Brett H Herzog; Minjia Sheng; Jianxin Fu; J Michael McDaniel; Hong Chen; Jia Ruan; Lijun Xia
Journal:  Cancer Res       Date:  2013-10-24       Impact factor: 12.701

8.  Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Authors:  James N Gerson; Elizabeth Handorf; Diego Villa; Alina S Gerrie; Parv Chapani; Shaoying Li; L Jeffrey Medeiros; Michael I Wang; Jonathon B Cohen; Oscar Calzada; Michael C Churnetski; Brian T Hill; Yazeed Sawalha; Francisco J Hernandez-Ilizaliturri; Shalin Kothari; Julie M Vose; Martin A Bast; Timothy S Fenske; Swapna Narayana Rao Gari; Kami J Maddocks; David Bond; Veronika Bachanova; Bhaskar Kolla; Julio Chavez; Bijal Shah; Frederick Lansigan; Timothy F Burns; Alexandra M Donovan; Nina Wagner-Johnston; Marcus Messmer; Amitkumar Mehta; Jennifer K Anderson; Nishitha Reddy; Alexandra E Kovach; Daniel J Landsburg; Martha Glenn; David J Inwards; Reem Karmali; Jason B Kaplan; Paolo F Caimi; Saurabh Rajguru; Andrew Evens; Andreas Klein; Elvira Umyarova; Bhargavi Pulluri; Jennifer E Amengual; Jennifer K Lue; Catherine Diefenbach; Richard I Fisher; Stefan K Barta
Journal:  J Clin Oncol       Date:  2019-01-07       Impact factor: 44.544

9.  Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family.

Authors:  Patrick Viatour; Tim C Somervaille; Shivkumar Venkatasubrahmanyam; Scott Kogan; Margaret E McLaughlin; Irving L Weissman; Atul J Butte; Emmanuelle Passegué; Julien Sage
Journal:  Cell Stem Cell       Date:  2008-10-09       Impact factor: 24.633

10.  Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.

Authors:  Mehdi Hamadani; Don M Benson; Craig C Hofmeister; Patrick Elder; William Blum; Pierluigi Porcu; Ramiro Garzon; Kristie A Blum; Thomas S Lin; Guido Marcucci; Steven M Devine
Journal:  Biol Blood Marrow Transplant       Date:  2009-03-09       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.